These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26161543)

  • 1. Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Sutton J; Bolton G; Zhou D; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    PLoS One; 2015; 10(7):e0132282. PubMed ID: 26161543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
    Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X
    Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
    Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
    Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of an Enzymatic Antibody-Drug Conjugation Approach Based on Coenzyme A Analogs.
    Grünewald J; Jin Y; Vance J; Read J; Wang X; Wan Y; Zhou H; Ou W; Klock HE; Peters EC; Uno T; Brock A; Geierstanger BH
    Bioconjug Chem; 2017 Jul; 28(7):1906-1915. PubMed ID: 28590752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species.
    Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
    Xenobiotica; 2024 Aug; 54(8):511-520. PubMed ID: 38647387
    [No Abstract]   [Full Text] [Related]  

  • 8. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
    Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
    Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.
    Shah DK; King LE; Han X; Wentland JA; Zhang Y; Lucas J; Haddish-Berhane N; Betts A; Leal M
    AAPS J; 2014 May; 16(3):452-63. PubMed ID: 24578215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
    Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
    Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry.
    Inoue K; Mochizuki T; Kasamori N; Komori T
    Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auristatin antibody drug conjugate physical instability and the role of drug payload.
    Adem YT; Schwarz KA; Duenas E; Patapoff TW; Galush WJ; Esue O
    Bioconjug Chem; 2014 Apr; 25(4):656-64. PubMed ID: 24559399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
    Greene MK; Chen T; Robinson E; Straubinger NL; Minx C; Chan DKW; Wang J; Burrows JF; Van Schaeybroeck S; Baker JR; Caddick S; Longley DB; Mager DE; Straubinger RM; Chudasama V; Scott CJ
    Br J Cancer; 2020 Nov; 123(10):1502-1512. PubMed ID: 32913288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.